Han Xue, Bai Bei-Bei, Feng Cui-Cui, Zhao Sen, Chen Ye
Department of Hematology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Department of Hematology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China .E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):190-196. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.030.
To analyze the mutant spectrum of clonal hematopoiesis of indeterminate potential (CHIP) related mutations and clinical characteristics and to explore the correlation and the possible mechanism between CHIP-related mutations and cardio-cerebrovasculars events (CCEs) in patients with myeloproliferative neoplasms (MPNs).
The clinical data and next-generation sequencing results of 73 MPN patients in Beijing Anzhen Hospital from August 2019 to July 2022 were retrospectively analyzed. Statistical analyses were conducted by multivariate logistic regression for the effects of CHIP-related mutations and inflammatory cytokines on CCEs for MPNs patients.
Fifty-five cases of MPN (75.3%) showed positive in CHIP-related genes. There was no significant difference in variant allele frequency of CHIP-related gene between essential thrombocythemia (ET) and polycythemia vera (PV). CHIP-related gene mutations were mainly single gene mutations, with mutation rate from high to low as (63.0%, 46/73), (16.4%, 12/73), (11.0%, 8/73), (9.6%, 7/73), (6.9%, 5/73), (4.1%, 3/73), (1.4%, 1/73) and (1.4%, 1/73). The mutation rate of CHIP-related genes in MPN patients >60 years old was significantly higher than that in the patients ≤60 years old [91.7%(33/36) 59.5%(22/37)]. CCEs occurred in 27 MPNs patients (37.0%, MPNs/CCEs), and 5 had recurrent CCEs, all of which were arterial events. Age (62.8±12.8 years 53.9±15.8 years, =0.015), IL-1β level (17.7±26.0 4.3±8.6, =0.012), IL-8 level (360.7±598.6 108.3±317.0, =0.045), the proportion of the patients with thrombosis history (29.6% 2.2%, =0.020), and the detection rate of CHIP-related mutations (88.9% 67.4%, =0.040) in the group with CCEs were higher than those in the group without CCEs. Multivariate Logistic regression analysis showed that age( =0.917, 95% :0.843-0.999, =0.047), thrombosis history ( =34.148, 95% :2.392-487.535, =0.009), any CHIP-related mutations( =16.065, 95% :1.217-212.024, =0.035), and elevated level of IL-1β ( =0.929, 95% :0.870-0.992, =0.027) were independent risk factors for MPNs/CCEs. CHIP-related gene mutations were not associated with CCEs in MPN patients, but ( =88.717, 95% :2.690-292.482, =0.012) and ( =7.941, 95% :1.045-60.353, =0.045) were independent risk factors for CCEs in PV.
There is a higher mutation rate of CHIP-related genes in MPN patients, especially those over 60 years old. Older age, thrombosis history, CHIP-related mutations and IL-1β elevated levels are independent risk factors for CCEs in MPN. and mutations are independent risk factors for CCEs in PV patients. CHIP-related gene mutations and inflammatory cytokine IL-1 β elevated levels may be the novel risk factors for CCEs in MPN.
分析潜在不确定性克隆性造血(CHIP)相关突变的突变谱及临床特征,探讨CHIP相关突变与骨髓增殖性肿瘤(MPN)患者心脑血管事件(CCE)之间的相关性及可能机制。
回顾性分析2019年8月至2022年7月在北京安贞医院就诊的73例MPN患者的临床资料及二代测序结果。采用多因素logistic回归分析CHIP相关突变和炎性细胞因子对MPN患者CCE的影响。
55例MPN患者(75.3%)CHIP相关基因呈阳性。原发性血小板增多症(ET)和真性红细胞增多症(PV)患者CHIP相关基因的变异等位基因频率无显著差异。CHIP相关基因突变主要为单基因突变,突变率由高到低依次为(63.0%,46/73)、(16.4%,12/73)、(11.0%,8/73)、(9.6%,7/73)、(6.9%,5/73)、(4.1%,3/73)、(1.4%,1/73)和(1.4%,1/73)。年龄>60岁的MPN患者CHIP相关基因的突变率显著高于≤60岁的患者[91.7%(33/36)对59.5%(22/37)]。27例MPN患者发生CCE(37.0%,MPN/CCE),5例发生复发性CCE,均为动脉事件。CCE组患者的年龄(62.8±12.8岁对53.9±15.8岁,P=0.015)、IL-1β水平(17.7±26.0对4.3±8.6,P=0.012)、IL-8水平(360.7±598.6对108.3±317.0,P=0.045)、有血栓形成史的患者比例(29.6%对2.2%,P=0.020)及CHIP相关突变的检出率(88.9%对67.4%,P=0.040)均高于无CCE组。多因素logistic回归分析显示,年龄(P=0.917,95%CI:0.843-0.999,P=0.047)、血栓形成史(P=34.1,48,95%CI:2.392-487.535,P=0.009)、任何CHIP相关突变(P=16.065,95%CI:1.217-212.024,P=0.035)及IL-1β水平升高(P=0.929,95%CI:0.870-0.992,P=0.027)是MPN/CCE的独立危险因素。CHIP相关基因突变与MPN患者的CCE无关,但(P=88.717,95%CI:2.690-292.482,P=0.012)和(P=7.941,95%CI:1.045-60.353,P=0.045)是PV患者CCE的独立危险因素。
MPN患者中CHIP相关基因的突变率较高,尤其是60岁以上患者。年龄较大、有血栓形成史、CHIP相关突变及IL-1β水平升高是MPN患者发生CCE的独立危险因素。和突变是PV患者发生CCE的独立危险因素。CHIP相关基因突变和炎性细胞因子IL-1β水平升高可能是MPN患者发生CCE的新危险因素。